Physician profile
Sergey Rome
NPI 1568431070
$1,180.77
in general payments reported to CMS, 2019-2025
25 companies · $163 in 2025
The $163 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $571 · 2020: $78.32 · 2021: $239 · 2022: $15.00 · 2023: $114 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $277.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $277.17 | 2023-2025 | Jelmyto |
| Pfizer INC. | $181.23 | 2019-2020 | |
| Boston Scientific Corporation | $110.81 | 2019-2021 | |
| Astellas Pharma US INC | $84.09 | 2019-2021 | |
| 180 Medical, INC. | $56.48 | 2019-2021 | |
| Coloplast Corp | $42.04 | 2019 | |
| Ferring Pharmaceuticals INC. | $40.90 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $39.46 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.27 | 2019-2021 | |
| Clarus Therapeutics INC. | $30.00 | 2021 | |
| Antares Pharma, INC. | $29.37 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $28.80 | 2019-2021 | |
| Urovant Sciences INC | $27.51 | 2021 | |
| Janssen Biotech, INC. | $27.04 | 2019-2021 | |
| Rochester Medical Corporation | $22.21 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $17.66 | 2021 | |
| Abbvie INC. | $15.00 | 2019 | |
| Glaxosmithkline, LLC. | $15.00 | 2022 | |
| Acerus Pharmaceuticals Corporation | $14.87 | 2021 | |
| Avadel Specialty Pharmaceuticals, LLC | $14.35 | 2019 | |
| Mission Pharmacal Company | $14.20 | 2019 | |
| Dendreon Pharmaceuticals LLC | $13.98 | 2020 | |
| Dentsply Ih INC. | $13.94 | 2021 | |
| Aytu Biopharma, INC. | $13.29 | 2020 | |
| Allergan, INC. | $13.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergey Rome listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.